Recent Updates — JAZZ
Jazz Pharmaceuticals plc estimates that its third-quarter 2026 financial results will include a pre-tax charge of approximately $755 million for acquired in-process research and development (IPR&D) related to the completed acquisition of Actio Biosciences, Inc. This non-deductible expense is expected to reduce both GAAP and non-GAAP adjusted earnings per share by approximately $11.00. The company notes that Q3 results are not yet finalized and actual figures may differ from these preliminary estimates. Jazz Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of medicines for serious diseases.
Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals plc, notified the company on October 6, 2026, of her intent to retire. Her departure will occur upon the earlier of the selection and appointment of a successor or June 30, 2027. The company plans to commence a formal search process for her replacement, considering both internal and external candidates. Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases.
On September 23, 2026, Jazz Pharmaceuticals plc extended the maturity of its U.S. dollar term loan B-2 facility to May 5, 2033, and repriced the debt through Amendment No. 4 to its Credit Agreement. Existing lenders converted outstanding Tranche B-2 loans into a new Tranche B-3 tranche with substantially similar terms but reduced margins: 1.75% over Term SOFR (down 50 basis points) or 0.75% over the prime lending rate, subject to a 0.50% SOFR floor. The company borrowed an additional $273,310,355.18 in Tranche B-3 loans to repay non-converted balances, bringing the total principal of the new tranche to $1,895,000,000. The debt amortizes quarterly at 0.25% of the initial principal amount. Jazz Pharmaceuticals plc operates in the pharmaceutical industry, developing and commercializing medicines for rare diseases.
Jazz Pharmaceuticals plc completed its acquisition of Actio Biosciences, Inc., a Delaware corporation, for an upfront payment of $820 million on September 15, 2026. Following the transaction, Actio became a wholly-owned subsidiary of Jazz. The acquisition adds ABS-1230, a clinical-stage potential first-in-class precision therapy targeting KCNT1-related epilepsy, to Jazz's pipeline. ABS-1230 is an orally available small molecule KCNT1 inhibitor that has received Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations from the U.S. FDA. Actio spun out non-ABS-1230 programs into a new private entity funded by existing investors, with Jazz retaining a minority stake. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing life-changing medicines for patients with rare diseases.
Jazz Pharmaceuticals plc completed a private offering of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, including the full exercise of the initial purchasers' option to purchase an additional $150 million. Net proceeds are estimated at approximately $1,226.4 million for general corporate purposes. Concurrently, the company repurchased approximately $225.0 million of its ordinary shares from note purchasers at a price of $249.29 per share using existing cash on hand, reducing the remaining authorization under its July 2024 buyback program. The notes mature on September 15, 2032, with semi-annual interest payments beginning March 15, 2027, and an initial exchange rate of 2.8150 ordinary shares per $1,000 principal amount. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing treatments for rare diseases.
On August 25, 2026, the U.S. Food and Drug Administration approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approvals cover Ziihera combined with Tevimbra (tislelizumab-jsgr) and chemotherapy for all HER2+ patients, as well as Ziihera plus chemotherapy for HER2+ IHC 3+ patients. This approval is based on the Phase 3 HERIZON-GEA-01 trial, which reported a median overall survival of 26.4 months versus 19.2 months for the control arm. Jazz Pharmaceuticals plc operates in the biopharmaceutical industry, developing and commercializing medicines for rare diseases, including cancers and sleep disorders.